SHR-8068
Hengrui's $180M CTLA-4 Antibody SHR‑8068 Enters Late-Stage Lung Cancer Trial
Hengrui’s CTLA-4 antibody SHR‑8068, licensed from CStone in a 1.3B RMB deal, is now in Phase III trials for lung cancer, competing in a space dominated globally by ipilimumab and tremelimumab. Innovent’s IBI310 is under review.